European Journal of Heart Failure, Год журнала: 2022, Номер 24(9), С. 1504 - 1505
Опубликована: Июль 19, 2022
Язык: Английский
European Journal of Heart Failure, Год журнала: 2023, Номер 25(7), С. 1115 - 1131
Опубликована: Май 18, 2023
Язык: Английский
Процитировано
46
ESC Heart Failure, Год журнала: 2024, Номер unknown
Опубликована: Май 28, 2024
Abstract In the last years, major progress has occurred in heart failure (HF) management. The 2023 ESC focused update of 2021 HF guidelines introduced new key recommendations based on results years science. First, two drugs, sodium–glucose co‐transporter‐2 (SGLT2) inhibitors and finerenone, a novel nonsteroidal, selective mineralocorticoid receptor antagonist (MRA), are recommended for prevention patients with diabetic chronic kidney disease (CKD). Second, SGLT2 now treatment across entire left ventricular ejection fraction spectrum. benefits quadruple therapy reduced (HFrEF) well established. Its rapid early up‐titration along close follow‐up frequent clinical laboratory re‐assessment after an episode acute (the so‐called ‘high‐intensity care’ strategy) was associated better outcomes STRONG‐HF trial. Patients experiencing worsening might require fifth drug, vericiguat. STEP‐HFpEF‐DM STEP‐HFpEF trials, semaglutide 2.4 mg once weekly administered 1 year decreased body weight significantly improved quality life 6 min walk distance obese preserved (HFpEF) or without history diabetes. Further data safety efficacy, including also hard endpoints, needed to support addition acetazolamide hydrochlorothiazide standard diuretic regimen hospitalized due HF. meantime, PUSH‐AHF supported use natriuresis‐guided therapy. options most recent evidence HF, specific drugs cardiomyopathies (i.e., mavacamten hypertrophic cardiomyopathy tafamidis transthyretin cardiac amyloidosis), device therapies, contractility modulation percutaneous valvulopathies, finding from TRILUMINATE Pivotal trial, reviewed this article.
Язык: Английский
Процитировано
38
ESC Heart Failure, Год журнала: 2022, Номер 9(6), С. 3667 - 3693
Опубликована: Дек. 1, 2022
Abstract In the last years, major progress occurred in heart failure (HF) management. Quadruple therapy is now mandatory for all patients with HF reduced ejection fraction. Whilst verciguat becoming available across several countries, omecamtiv mecarbil waiting to be released clinical use. Concurrent use of potassium‐lowering agents may counteract hyperkalaemia and facilitate renin–angiotensin–aldosterone system inhibitor implementations. The results EMPagliflozin outcomE tRial Patients With chrOnic heaRt Failure Preserved Ejection Fraction (EMPEROR‐Preserved) trial were confirmed by Dapagliflozin Heart Mildly Reduced or (DELIVER) trial, we have, first time, evidence treatment also preserved a pre‐specified meta‐analysis randomized controlled trials, sodium–glucose co‐transporter‐2 inhibitors all‐cause mortality, cardiovascular (CV) hospitalization regardless left ventricular Other steps forward have decompensated HF. Acetazolamide Acute Decompensated Volume Overload (ADVOR) showed that addition intravenous acetazolamide loop diuretics leads greater decongestion vs. placebo. hydrochlorothiazide was evaluated CLOROTIC trial. Torasemide did not change outcomes, compared furosemide, TRANSFORM‐HF. Ferric derisomaltose had an effect on primary outcome CV mortality rehospitalizations IRONMAN (rate ratio 0.82; 95% confidence interval 0.66–1.02; P = 0.070). Further options HF, including device therapies, cardiac contractility modulation, percutaneous valvulopathies, are summarized this article.
Язык: Английский
Процитировано
49
European Journal of Heart Failure, Год журнала: 2023, Номер 26(2), С. 327 - 337
Опубликована: Ноя. 7, 2023
Persistent symptoms despite guideline-directed medical therapy (GDMT) and poor tolerance of GDMT are hallmarks patients with advanced heart failure (HF) reduced ejection fraction (HFrEF). However, real-world data on use, dose, prognostic implications lacking.
Язык: Английский
Процитировано
29
European Journal of Heart Failure, Год журнала: 2024, Номер 26(7), С. 1585 - 1593
Опубликована: Май 29, 2024
Язык: Английский
Процитировано
12
Journal of Cardiovascular Medicine, Год журнала: 2024, Номер unknown
Опубликована: Янв. 10, 2024
Aims To evaluate the role of tricuspid regurgitation in advanced heart failure. Methods The multicenter observational HELP-HF registry enrolled consecutive patients with failure and at least one ‘I NEED HELP’ criterion evaluated four Italian centers between January 2020 November 2021. Patients no data on and/or receiving valve intervention during follow-up were excluded. population was stratified by no/mild vs. moderate severe regurgitation. Variables independently associated regurgitation, as well association clinical outcomes investigated. primary outcome all-cause mortality. Results Among 1085 included this study, 508 (46.8%) had 373 (34.4%) 204 (18.8%) History atrial fibrillation, any prior surgery, high dose furosemide, preserved left ventricular ejection fraction, moderate/severe mitral pulmonary hypertension found to be an increased likelihood Estimated rates 1-year death 21.4, 24.5 37.1% respectively (log-rank P < 0.001). As compared nonsevere a higher risk mortality (adjusted hazard ratio 1.38, 95% confidence interval 1.01–1.88, = 0.042), whereas did not. Conclusion In contemporary, real-world cohort failure, several echocardiographic characteristics are have
Язык: Английский
Процитировано
9
European Journal of Heart Failure, Год журнала: 2025, Номер unknown
Опубликована: Янв. 20, 2025
Abstract Aims Accurate selection of patients with severe heart failure (HF) who might benefit from advanced therapies is crucial. The present study investigates the performance available risk scores aimed at predicting mortality in HF. Methods and results 1‐year was estimated HF enrolled HELP‐HF cohort according to MAGGIC, 3‐CHF, ADHF/NT‐proBNP, GWTG‐HF scores, number criteria 2018 HFA‐ESC definition HF, I NEED HELP markers, domains fulfilled 2019 frailty, frailty index, INTERMACS profile. In addition, we tested different machine learning (ML)‐based models predict mortality. At follow‐up, 265 (23.1%) died. prognostic accuracy, subgroup completeness all data regarding variables included (497/1149 patients), resulted moderate for GWTG‐HF, ADHF/NT‐proBNP (area under curve [AUC] ≥0.70) only poor other tools. All lost accuracy estimating rate highest risk. Support vector machine‐based model had best AUC among ML‐based models, slightly outperforming most scores. Conclusion Most used performed poorly real‐world provided inaccurate estimate did not significantly outperform currently their use must be validated large patients.
Язык: Английский
Процитировано
1
European Journal of Heart Failure, Год журнала: 2024, Номер 26(6), С. 1399 - 1407
Опубликована: Май 14, 2024
Abstract Aims Frailty is highly prevalent in patients with heart failure (HF), but a concordant definition of this condition lacking. The Heart Failure Association the European Society Cardiology (HFA‐ESC) proposed 2019 new multi‐domain frailty, it has never been validated. Methods and results Patients from HELP‐HF registry were stratified according to number HFA‐ESC frailty domains fulfilled cumulative deficits index (FI) quintiles. Prevalence each domain was reported, as well rate composite all‐cause death HF hospitalization, its single components, cardiovascular group quintile. Among 854 included patients, 37 (4.3%), 206 (24.1%), 365 (42.8%), 217 (25.4%), 29 (3.4%) zero, one, two, three, or four domains, respectively, while 179 had FI < 0.21 considered not frail. 1‐year risk adverse events increased proportionally (for criterion increase, hospitalization: hazard ratio [HR] 1.43, 95% confidence interval [CI] 1.27–1.62; death: HR 1.72, CI 1.46–2.02, hospitalizations: subHR 1.21, 1.04–1.31; 1.77, 1.45–2.15). Consistent found stratifying cohort for continuous variable demonstrated higher discriminative ability than (area under curve = 0.68 vs. 0.64, p 0.004). Conclusion at advanced HF, assessed via approach FI, identifies those events. be slightly more effective identifying mortality.
Язык: Английский
Процитировано
6
Circulation Heart Failure, Год журнала: 2023, Номер 16(12)
Опубликована: Ноя. 1, 2023
The "I Need Help" markers have been proposed to identify patients with advanced heart failure (HF). We evaluated the prognostic impact of these on clinical outcomes in a real-world, contemporary, multicenter HF population.
Язык: Английский
Процитировано
13
Current Problems in Cardiology, Год журнала: 2025, Номер 50(7), С. 103068 - 103068
Опубликована: Май 6, 2025
Язык: Английский
Процитировано
0